Early clinical trials of mRNA therapeutics include studies of paracrine vascular endothelial growth factor (VEGF) mRNA for heart failure and CRISPR-Cas9 mRNA for a congenital liver-specific storage disease. Here, VEGFA is linked to heart failure.